SCHEMBL6078620

SCHEMBL6078620

CCOc1ccc(NC(=O)Nc2ccc3oc(=O)cc(C(F)(F)F)c3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
PAX8 Q06710 2/20 0.55
LMNA P02545 2/20 0.55
MAP2K1 Q02750 1/20 0.53
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 4/20 0.49
POLB P06746 3/20 0.48
CA9 Q16790 1/20 0.48
AGER Q15109 1/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MITF O75030 1/20 0.47
HSD17B10 Q99714 1/20 0.47
AR P10275 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078413 0.86 EPHX2 (0.57) KMT2AMEN1MAP2K1ALDH1A1HTT
SCHEMBL6077634 0.84 MAP2K1 (0.51) KMT2AMAP2K1CA9AGERAR
SCHEMBL6077814 0.82 CA9 (0.56) KMT2AMEN1LMNAMAP2K1ALDH1A1
SCHEMBL6076371 0.79 CA9 (0.55) KMT2AMEN1MAP2K1ALDH1A1KDM4E
SCHEMBL6077260 0.78 CA9 (0.61) KMT2AMEN1MAP2K1ALDH1A1KDM4E
SCHEMBL6077825 0.78 MAP2K1 (0.52) KMT2AMEN1MAP2K1ALDH1A1HTT
SCHEMBL6081603 0.77 MAP2K1 (0.61) KMT2AMEN1MAP2K1ALDH1A1KDM4E
SCHEMBL4118152 0.76 LMNA (0.72) KMT2AMEN1PAX8LMNAMAP2K1
SCHEMBL238765 0.75 AGER (0.70) AGERAR
SCHEMBL5860370 0.75 MAPT (0.49) KMT2AMEN1LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074933-B2 Urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-07-11 US claimed
EP-1603882-A2 UREA AND THIOUREA DERIVATIVES Warner-Lambert Company LLC (US) 2005-12-14 EP claimed
WO-2004072044-A2 UREA AND THIOUREA DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO claimed
US-7074933-B2 Urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-07-11 US disclosed
EP-1603882-A2 UREA AND THIOUREA DERIVATIVES Warner-Lambert Company LLC (US) 2005-12-14 EP disclosed
US-20040266820-A1 Urea and thiourea derivatives DU DANIEL Y (US) 2004-12-30 US disclosed
WO-2004072044-A2 UREA AND THIOUREA DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266820-A1 Urea and thiourea derivatives SHBG, ZP1, ZYX KMT2A 915/4885MEN1 116/4885PAX8 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.